BARCELONA, Spain, May 22, 2007 /PRNewswire/ -- Principal
investigators for the COSTAR II (CObalt Chromium STent with
Antiproliferative for Restenosis) trial, the pivotal study for the
CoStar(R) cobalt chromium paclitaxel-eluting coronary stent,
presented today the clinical trial results of the study at EuroPCR
2007. The investigators confirmed that the study failed to meet its
primary endpoint. Conor previously announced this conclusion in a
press release on Monday, May 7, 2007.

The COSTAR II trial compared the CoStar(R) stent with the Taxus
Express(2) paclitaxel drug-eluting stent, and was designed to
demonstrate non-inferiority at eight-month follow-up with respect
to major adverse cardiac events (MACE) in patients with
multi-vessel or single-vessel disease. In this trial, MACE was
defined as a composite of clinically driven target vessel
revascularization (re-treatment), new myocardial infarction (heart
attack or MI) related to the target vessel and cardiac death
related to an intervened vessel.

At eight-month follow-up, the CoStar(R) stent had significantly
higher MACE rate than the Taxus stent (11.0 percent vs. 6.9
percent; p=0.005). This difference was largely due to a
significantly higher incidence of clinically driven target vessel
revascularization (8.1 percent vs. 4.3 percent; p=0.002). No
significant differences were found in terms of cardiac death (0.5
percent for the CoStar(R) stent vs. 0.7 percent for the Taxus
stent; p=0.541) or new MI (3.4 percent vs. 2.4 percent;
p=0.242).

The investigators also reported that the protocol-defined stent
thrombosis rates at nine-month were similar between both arms of
the study. The total stent thrombosis rate for the CoStar(R) stent
was 0.6 percent vs. 0.1 percent for the Taxus stent (p=0.252).

"Comparably higher re-intervention rates are largely responsible
for the outcome of this trial," said Mitchell W. Krucoff, M.D.,
from Duke Cli
nical Research Institute in Durham, North Carolina,
who presented the primary results of the study at the conference as
a global co-principal investigator. "The safety data from this
trial are consistent with other drug-eluting stent studies."

As a result of these outcomes, Conor Medsystems LLC recently
terminated ongoing clinical trials with the CoStar(R) stent and
halted the submission of its Pre-Market Approval application to the
U.S. Food and Drug Administration for the product. Further, Conor
Medsystems discontinued sale of the product through commercial
partners in countries in Europe, Asia and Latin America where the
CoStar stent was already approved.

The company cited potentially sub-optimal therapeutic dosing of
paclitaxel as the potential reason why the COSTAR II Trial failed
to meet its primary endpoint. Going forward, the company's clinical
program will be heavily focused on the study of sirolimus on its
platform, as well as on investigating the vast library of
therapeutic agents accessible to its scientists through the
research and development programs of pharmaceutical companies in
the Johnson & Johnson family of companies.

"We remain optimistic about the ability of the novel Conor
Medsystems reservoir platform to provide precise and controlled
delivery of a therapeutic agent based on earlier proof of concept
testing and trials," said Campbell Rogers, M.D., chief technology
officer, Johnson & Johnson cardiovascular franchise. "We expect
that the continued development of sirolimus on this platform will
demonstrate promising outcomes because sirolimus has been shown to
be a versatile and potent anti-restenosis agent with a wide
therapeutic dosing range."

Sirolimus is the proven drug used with the CYPHER(R)
Sirolimus-eluting Coronary Stent -- the most widely studied
coronary stent in the world.

(Date:12/8/2016)... , Dec. 8, 2016 IRIDEX Corporation (NASDAQ: ... offer newly issued shares of common stock, $0.01 par value ... an underwritten public offering. The final terms of the Offering ... of pricing, and there can be no assurance as to ... IRIDEX expects to use the net proceeds it will receive ...

(Date:12/8/2016)... -- Global Interventional Radiology Market: Scope and Methodology ... market analyzes the current and future prospects of ... summary, including a market snapshot that provides overall ... research is a combination of primary and secondary ... research efforts along with information collected from telephonic ...

(Date:12/8/2016)... 2016 Eli Lilly and Company (NYSE: ... 3 EXPEDITION3 trial at the 9 th Clinical ... solanezumab did not meet the primary endpoint in the ... people with mild dementia due to Alzheimer,s disease (AD), ... for the treatment of mild dementia due to AD. ...

(Date:12/8/2016)... San Francisco, California (PRWEB) , ... December 08, 2016 , ... ... health coaches, has raised an $18M Series B led by Canvas Ventures . ... use the capital to scale its mobile platform to serve more consumers who are ...

(Date:12/8/2016)... ... December 08, 2016 , ... The Dan Carlisle Agency, ... Jefferson County, is announcing the launch of a charity drive to raise support ... homeless women and children in Birmingham has grown steadily since the 1980’s, and ...

(Date:12/8/2016)... , ... December 08, 2016 , ... The Compretta Insurance ... and residential clients in and around the Hancock County area, is announcing the launch ... County Food Pantry. , The Hancock County Food Pantry has worked for more than ...

(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... DrugDev ... the announcement that it is one of the early adopters completing EU-U.S. Privacy Shield ... is designed to provide companies on both sides of the Atlantic with a mechanism ...

(Date:12/7/2016)... Kenosha, Wisconsin (PRWEB) , ... December 07, 2016 , ... ... the extraordinary new MedMaster™ MPCNGX . The MPCNGX is a multi-function, sealed, LED ... the right amount of light where and when it’s needed. , A ...